Abstract: |
Bimolane has been shown to have good antitumor activity and on an equitoxic basis its activity is usually better than the chemically related razoxane. Resistance patterns of these two piperazinediones were similar. They exhibited cross-resistance to each other but little or no cross-resistance to most other clinically used drugs tested. Partial resistance was observed, however, between the piperazinediones and vincristine, daunorubicin and doxorubicin. The antitumor activities of three new analogs were compared with bimolane, ICRF-154 and razoxane against four rodent tumors. In general, bimolane was most effective. © 1985. |
Keywords: |
osteosarcoma; cancer chemotherapy; doxorubicin; fluorouracil; drug efficacy; nonhuman; cytarabine; methotrexate; antineoplastic agent; mouse; animal; mice; biological model; lung neoplasms; animal experiment; cyclophosphamide; melphalan; vincristine; drug resistance; drug screening; mice, inbred strains; drug mechanism; daunorubicin; bone; neoplasms, experimental; piperazines; drug cytotoxicity; therapy; lewis carcinoma; mercaptopurine; intoxication; respiratory system; drug comparison; razoxane; intraperitoneal drug administration; leukemia l1210; female; priority journal; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; leukemia l 1210; sarcoma 180; blood and hemopoietic system; 1,2 bis(3,5 dioxopiperazin 1 yl)ethane; bimolane; 1,2 bis[3,5 dioxo 4 (maleic hydrazidomethyl)piperazin 1 yl]ethane; 1,2 bis[3,5 dioxo 4 (maleimidomethyl)piperazin 1 yl]ethane; 1,2 bis[4 (2 amino 1,3,4 thiadiazolomethyl) 3,5 dioxopiperazin 1 yl]ethane; 2,5 piperazinedione derivative; 2,6 piperazinedione derivative; cell strain ros
|